Abstract
The effect of combining RDC-11 (a new ruthenium organometallic complex) and fast neutrons (high-LET radiations) has been evaluated in RDM4 and U-87 tumor cell lines. After co-treatment, a substantial reduction of cell growth was recorded, which appears not to be correlated with the induction of apoptosis.
Keywords: Ruthenium-based anticancer drugs, Apoptosis, High-LET radiation, Concomitant chemoradiotherapy, Fast neutrons
Letters in Drug Design & Discovery
Title: Evaluation of the Ability of an Organic Derivative of Ruthenium(II) to Reinforce the Cytotoxicity of Fast Neutron Against Malignant Cells in Culture
Volume: 5 Issue: 1
Author(s): P. Bischoff, L. Leyva, F. Malek, S. Benzina, J. M. Denis, J. Gueulette, P. Dufour, C. Gaiddon, J. P. Loeffler, C. Sirlin and M. Pfeffer
Affiliation:
Keywords: Ruthenium-based anticancer drugs, Apoptosis, High-LET radiation, Concomitant chemoradiotherapy, Fast neutrons
Abstract: The effect of combining RDC-11 (a new ruthenium organometallic complex) and fast neutrons (high-LET radiations) has been evaluated in RDM4 and U-87 tumor cell lines. After co-treatment, a substantial reduction of cell growth was recorded, which appears not to be correlated with the induction of apoptosis.
Export Options
About this article
Cite this article as:
Bischoff P., Leyva L., Malek F., Benzina S., Denis M. J., Gueulette J., Dufour P., Gaiddon C., Loeffler P. J., Sirlin C. and Pfeffer M., Evaluation of the Ability of an Organic Derivative of Ruthenium(II) to Reinforce the Cytotoxicity of Fast Neutron Against Malignant Cells in Culture, Letters in Drug Design & Discovery 2008; 5 (1) . https://dx.doi.org/10.2174/157018008783406714
DOI https://dx.doi.org/10.2174/157018008783406714 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
miRNAs in Bone Development
Current Genomics Insight View on Possible Role of Fluoroquinolones in Cancer Therapy
Current Topics in Medicinal Chemistry Aggrecanase: The Family and Its Inhibitors
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Molecular Links Between Diabetes and Osteoarthritis: The Role of Physical Activity
Current Diabetes Reviews New Perspectives in the Pharmacological Potential of Naringin in Medicine
Current Medicinal Chemistry Interleukin-10 and Articular Cartilage: Experimental Therapeutical Approaches in Cartilage Disorders
Current Gene Therapy Cyclopamine, a Naturally Occurring Alkaloid, and Its Analogues May Find Wide Applications in Cancer Therapy
Current Topics in Medicinal Chemistry Flavonoids as Multi-Target Compounds in Drug Discovery
Mini-Reviews in Organic Chemistry Cartilage and Bone Extracellular Matrix
Current Pharmaceutical Design Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine microRNA in Chondrogenesis, Cartilage and Osteoarthritis
Current Rheumatology Reviews The Chick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-Angiogenesis
Current Pharmaceutical Biotechnology Combination Therapy of Cisplatin and other Agents for Osteosarcoma: A Review
Current Cancer Therapy Reviews Hijacking the Hedgehog Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry One Hundred Faces of Cyclopamine
Current Pharmaceutical Design Current State of ERG as Biomarker in Prostatic Adenocarcinoma
Current Cancer Drug Targets Image Guided Biopsy of Musculoskeletal Lesions with Low Diagnostic Yield
Current Medical Imaging Regulation of Autophagy by Sphingolipids
Anti-Cancer Agents in Medicinal Chemistry Peeking into the Black Box: How Cytokine Antibody Arrays Shed Light on Molecular Mechanisms of Breast Cancer Development and its Treatment
Current Proteomics Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets